a16z Capital Management, L.L.C.

Position in ERAS — Erasca, Inc.

CIK 1540358 MENLO PARK, CA

Position in ERAS

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$46,315,250

+$35,666,750 QoQ

Shares Held

2,862,500

0.0% QoQ

Ownership

0.920%

of shares outstanding

% of Portfolio

3.59%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2023

10 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

a16z Capital Management, L.L.C. holds $304,679,821 across 8 Biotechnology names. ERAS ranks #4 (15.2% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	RVMD	Revolution Medicines, Inc.	921,099	$89,576,877
2	NAUT	Nautilus Biotechnology, Inc.	17,653,917	$68,497,197
3	MAZE	Maze Therapeutics, Inc.	1,702,225	$50,811,416
4	ERAS	Erasca, Inc. This page	2,862,500	$46,315,250
5	DMRA	Damora Therapeutics, Inc.	1,236,157	$32,016,466
6	CAMP	Camp4 Therapeutics Corp	2,125,339	$9,372,744
7	AKTS	Aktis Oncology, Inc.	415,000	$7,424,350
8	DNA	Ginkgo Bioworks Holdings, Inc.	108,568	$665,521

10 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$46,315,250	2,862,500	0.0%	Shares	Sole	2026-05-15
2025-12-31	$10,648,500	2,862,500	0.0%	Shares	Sole	2026-02-17
2025-09-30	$6,240,250	2,862,500	0.0%	Shares	Sole	2025-11-14
2025-06-30	$3,635,375	2,862,500	0.0%	Shares	Sole	2025-08-14
2025-03-31	$3,921,625	2,862,500	0.0%	Shares	Sole	2025-05-15
2024-12-31	$7,184,875	2,862,500	0.0%	Shares	Sole	2025-02-12
2024-09-30	$7,814,625	2,862,500	0.0%	Shares	Sole	2024-11-13
2024-06-30	$6,755,500	2,862,500	0.0%	Shares	Sole	2024-08-13
2024-03-31	$5,896,750	2,862,500	0.0%	Shares	Sole	2024-05-15
2023-12-31	$6,097,125	2,862,500	—	Shares	Sole	2024-05-15
No filing history on record for this holder in this stock.